Cara Therapeutics (NASDAQ:CARA) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com started coverage on shares of Cara Therapeutics (NASDAQ:CARA) in a research note issued on Wednesday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Cara Therapeutics Stock Performance

NASDAQ:CARA opened at $0.33 on Wednesday. The stock’s 50-day moving average is $0.29 and its 200-day moving average is $0.40. Cara Therapeutics has a 1-year low of $0.24 and a 1-year high of $1.31. The stock has a market cap of $17.97 million, a P/E ratio of -0.16 and a beta of 0.68.

Cara Therapeutics (NASDAQ:CARA) last posted its earnings results on Wednesday, August 14th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.10). The business had revenue of $0.99 million for the quarter, compared to the consensus estimate of $1.26 million. Cara Therapeutics had a negative return on equity of 241.31% and a negative net margin of 1,010.20%. As a group, equities analysts forecast that Cara Therapeutics will post -1.24 EPS for the current year.

Hedge Funds Weigh In On Cara Therapeutics

A hedge fund recently raised its stake in Cara Therapeutics stock. Disciplined Growth Investors Inc. MN lifted its holdings in shares of Cara Therapeutics, Inc. (NASDAQ:CARA) by 6.6% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,935,718 shares of the biopharmaceutical company’s stock after purchasing an additional 120,660 shares during the period. Disciplined Growth Investors Inc. MN owned 3.54% of Cara Therapeutics worth $499,000 at the end of the most recent reporting period. 44.66% of the stock is currently owned by institutional investors.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.